Shares of United Therapeutics fell as much as 6 percent Monday after the company announced it would be delaying the launch of an implantable pump until 2018.
The pump treats patients with pulmonary arterial hypertension, a type of high blood pressure that affects arteries in the lungs and in the heart, by delivering prescription drug Remodulin.
“We are sorry to have missed our 2017 launch target, but it is a small miss in the context of our providing more U.S. pulmonary arterial hypertension patients with helpful medicines than any other company,” the pharmaceutical company said in a Monday statement.
